Trial · NCT07379827
Effectiveness and Adverse-effect Switch Evaluation of Xanomeline and Trospium Chloride (KarXT)
NCT07379827, Recruiting, Bristol-Myers Squibb
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. Effectiveness and Adverse-effect Switch Evaluation of Xanomeline and Trospium Chloride (KarXT). Trials, record NCT07379827. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07379827
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Effectiveness and Adverse-effect Switch Evaluation of Xanomeline and Trospium Chloride (KarXT)
- NCT number
- NCT07379827
- Status
- Recruiting
- Enrollment
- 1,500 participants, estimated
- Lead sponsor
- Bristol-Myers Squibb
- Conditions
- Schizophrenia
- Interventions
- Xanomeline and trospium chloride (KarXT)
- First posted
- 2026-02-02
- Last updated
- 2026-11-02
Source ClinicalTrials.gov
Registered outcomes17
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Treatment titration and switch regimens as described by the prescribing clinician | Baseline and up to 20 weeks | |
| Secondary | Adverse events (AEs) | Baseline and up to 20 weeks | |
| Secondary | Change in participant weight | Baseline and up to 20 weeks | |
| Secondary | Clinical Global Impressions - Improvement (CGI-I) score | Baseline and up to 20 weeks | |
| Secondary | Number of schizophrenia-related relapses (defined as schizophrenia-related emergency department visits and/or hospitalizations and symptoms | Baseline and up to 20 weeks | |
| Secondary | Continuation of treatment with xanomeline and trospium chloride (KarXT) at End of Study | Baseline and up to 20 weeks | |
| Secondary | Number of participants who discontinue treatment, time to discontinuation, and reasons for discontinuation | Baseline and up to 20 weeks | |
| Secondary | Number of participants using antiemetic treatment by type, duration, and resolution of event for xanomeline and trospium chloride (KarXT) related gastro-intestinal (GI) symptoms | Baseline and up to 20 weeks | |
| Secondary | Date of first xanomeline and trospium chloride (KarXT) treatment | Baseline | |
| Secondary | Participant age | Baseline |
1 to 10 of 17Source ClinicalTrials.gov
See all 17 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Source
- Release
- trials-2026-11-12-0.4.0
- Release manifest SHA-256
- 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4
- Registry capture
- 2026-11-12
- Results copy, AACT
- 2026-03-23
- NIH clinical studies file
- 2026-11-13
Source ClinicalTrials.gov
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07379827
GET https://conductscience.org/api/trials/v1/NCT07379827/registered